Cited by 165Tuberous Sclerosis Complex ResearchPI3K/AKT/mTOR signaling in cancerGenetics and Neurodevelopmental Disorders

Neuronal and glia abnormalities in Tsc1-deficient forebrain and partial rescue by rapamycin

Open access
Carson, Robert P., Van Nielen, Dominic L., Winzenburger, Peggy A., Ess, Kevin C.·2012·Neurobiology of Disease

Abstract

Tuberous Sclerosis Complex (TSC) is a multiorgan genetic disease that prominently features brain malformations (tubers) with many patients suffering from epilepsy and autism. These malformations typically exhibit neuronal as well as glial cell abnormalities and likely underlie much of the neurological morbidity seen in TSC. Tuber pathogenesis remains poorly understood though upregulation of the mTORC1 signaling pathway in TSC has been consistently demonstrated. Here we address abnormal brain development in TSC by inactivating the mouse Tsc1 gene in embryonic neural progenitor cells. This strategy permits evaluation of the role of the Tsc1 gene in both neuronal as well as glial cell lineages. Tsc1(Emx1-Cre) conditional knockout (CKO) animals die by 25 days of life. Their brains have increased size and contain prominent large cells within the cerebral cortex that have greatly increased mTORC1 signaling and decreased mTORC2 signaling. Severe defects of cortical lamination, enlarged dysmorphic astrocytes and decreased myelination were also found. Tsc1(Emx1-Cre) CKO mice were then treated with rapamycin to see if the premature death and brain abnormalities can be rescued. Postnatal rapamycin treatment completely prevented premature death and largely reversed the glia pathology but not abnormal neuronal lamination. These findings support a model that loss of function of the TSC genes in embryonic neural progenitor cells causes cortical malformations in patients with TSC. The dramatic effect of rapamycin suggests that even with extensive multi-lineage abnormalities, a postnatal therapeutic window may exist for patients with TSC.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.nbd.2011.08.024

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Rapamycin successfully reduced cognitive impairment and social behavior deficit in mouse models of tuberous sclerosis and improved behavior in adult mice with a deletion of PTEN.

    “Rapamycin successfully reduced cognitive impairment and social behavior deficit in mouse models of tuberous sclerosis 61-63 and improved behavior in adult mice with a deletion of PTEN 64 .”

    From Progress toward treatments for synaptic defects in autism (2013) · cites this paper as [63]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Carson, R. P., Van Nielen, D. L., Winzenburger, P. A., & Ess, K. C.
Affiliations
Vanderbilt University (US)
Corresponding author
Ess, Kevin C.
Venue
Neurobiology of Disease
Publisher
Elsevier BV
Published
2012-01
Volume
45
Issue
1
Pages
369-380
ISSN
0969-9961 (ISSN-L)
OpenAlex
W2087441158
Cited by
165
References
49
Citations by year
2026: 2 · 2025: 10 · 2024: 8 · 2023: 9 · 2022: 11 · 2021: 9 · 2020: 8 · 2019: 4 · 2018: 8 · 2017: 14 · 2016: 15 · 2015: 17 · 2014: 15 · 2013: 20 · 2012: 15
FWCI
10.91
Type
journal article
Language
en
Open access
Locations
  • Neurobiology of Disease (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • NIH (5K08NS050484)
  • Vanderbilt Kennedy Center for Research on Human Development
  • Tuberous Sclerosis Alliance
Topics
  • Health Sciences › Medicine › Physiology › Tuberous Sclerosis Complex Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
Keywords
tuberous sclerosis complex, TSC1, mTORC1 signaling, mTORC2 signaling, rapamycin, cortical lamination, malformations of cortical development, astrocytes, myelination, conditional knockout mice, epilepsy, autism spectrum disorder
MeSH terms
Tuberous Sclerosis Complex 1 Protein, Animals, Brain, Disease Models, Animal, Neuroglia, Neurons, Transcription Factors, Tuberous Sclerosis, Signal Transduction, Cell Death, Mice, Knockout, Sirolimus, Tumor Suppressor Proteins, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review